About A public-private partnership that supports the discovery of new medicines through open access research. Mission and Philosophy Partners Governance Collaborators Laboratories Key Achievements Strategic Alliances and Communications FAQs Sitemap Science TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM PROTEIN STRUCTURES PUBLICATIONS CHEMICAL PROBES Epigenetics Probes Collection Human Kinase Chemical Probe Program Probes against other protein classes RECOMBINANT ANTIBODIES Structure-guided Drug Discovery Coalition (SDDC) CREATE ChemNET Research Program Trainees Open Access Learning Faculty & Industry Participants Structural & Chemical Biology Bootcamp Events Structural Biology Programme Structural Parasitology Rare Diseases Genome Integrity Growth Factor Signalling Integral Membrane Proteins Metabolic Enzymes Phosphorylation-Dependent Signalling Protein Kinases Ubiquitin Biology Chemical Biology Antibodies Protein Families Protein Methyltransferases Histone Deacetylases Histone Acetyltransferases Demethylases Bromodomains Methyl Lysine Readers Probe Development Screening Platforms Epigenetic Cell Assays Fragment Based Screening Informatics Medicinal Chemistry CHROMOHUB Phylogenetic Trees Histone Tails Epigenetics Pocketome Technological Science Biotechnology Biophysics Screening Platforms Research Informatics Protein Crystallography Medicinal Chemistry Reagents & Resources Reagents Chemical Probes Antibodies SGC Vectors SGC Plasmids SGC Constructs Resources Structure Gallery Protein Production Protocols CHROMOHUB Phylogenetic Trees Histone Tails Fragment Screening Crystal Forms Technologies High Throughput Protein Crystallisation Lex Bubbling System Frapid People Global SGC Director Aled Edwards Paul Van Damme Arij Al-Chawaf Wen Hwa Lee Amy Donner Academic Collaborators Industrial/ SME collaborators Non-Scientists Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Peter J. Brown Raymond Hui Jinrong Min Takis Prinos Matthieu Schapira Yufeng Tong Masoud Vedadi Oxford Chas Bountra Paul Brennan Alex N. Bullock Nicola Burgess-Brown Liz Carpenter Katharina Duerr Aude Echalier-Glazer Gillian Farnie Oleg Fedorov Panagis Filippakopoulos Opher Gileadi Kilian Huber Brian Marsden Fiona McCann Udo Oppermann Frank Von Delft Wyatt Yue UNICAMP Jon Elkins Paulo Arruda Katlin B. Massirer Mario H. Bengtson UNC Tim Willson Bill Zuercher Carrow Wells Alison Axtman David Drewry Karolinska Michael Sundström Susanne Gräslund Louise Berg Per-Johan Jakobsson Frankfurt Stefan Knapp Susanne Müller-Knapp News & Outreach News & Events SGC News Symposia & Workshops Blog Press Releases Public Events Public Engagement General Public Schools Media Patient Groups Governments TOronto Ubiquitin Club And Network (TOUCAN) Careers Tweets by thesgconline
A public-private partnership that supports the discovery of new medicines through open access research.
PFI-4 A chemical probe for BRPF1BThis probe is available from Sigma, Tocris and Cayman. group newOverviewBRPF1/2/3 are scaffolding proteins assembling HAT complexes of the MOZ/MORF family transcriptional coactivators (MOZ, Ybf2/Sas3, Sas2 and Tip60). BRPF1 links the catalytic HATs to the other subunits ING5 and hEAF6. Translocations of MOZ are associated with aggressive subtypes of leukemia, producing, for example, the MOZ-TIF2 fusion protein, which also interacts with BRPF1. BRPF1 is important for maintaining Hox gene expression and skeletal development in fish. BRPF1 exists in 2 different isoforms: BRPF1A and BRPF1B. A residue insertion in the ZA loop of BRPF1A prevents binding to acetylated histone peptides. BRPF1A may act as dominant negative isoform of BRPF1 generated by alternative splicing. A chemical probe for the bromodomains of the BRPF1B has been developed in collaboration with Pfizer. PFI-4 specifically binds to BRPF1B with a Kd =13 nM as determined by ITC. It reduces recovery time in U2OS cells transfected with a BRPF1B triple BRD construct with a nuclear localisation signal (NLS) in the FRAP assay at 500nM, while showing no effect on BRPF1A. A cellular target engagement assay evaluating the interaction of BRPF1B with histones suggested and EC50 of 250 nM for PFI-4. Properties Physical and chemical properties Molecular weight 380.45 Molecular formula C21H24N4O3 IUPAC name N-(1,3-dimethyl-2-oxo-6-(pyrrolidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-2-methoxybenzamide clogP 2.23 PSA 65.12 No. of chiral centres 0 No. of rotatable bonds 5 No. of hydrogen bond acceptors 4 No. of hydrogen bond donors 1 Storage Stable as solid in the dark at -20°C. NB making aliquots rather than freeze-thawing is recommended Dissolution Soluble in DMSO